Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group

European Journal of Cancer

Volumn 35, Issue 8, 1999, Pages 1194-1201

  Sjostrom J ^a   Blomqvist, C ^a   Mouridsen, H ^b   Pluzanska, A ^c   Ottosson Lonn S ^d   Bengtsson, N O ^e   Ostenstad B ^h   Mjaaland, I ⁱ   Palm Sjovall M ^f   Wist, E ^j   Valvere, V ^k   Anderson, H ^f   Bergh, J ^g  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Rigshospitalet   (Denmark)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

ⁱ STAVANGER UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^k Estonian Cancer Centre   (Estonia)

more..

Author keywords

5 Fluorouracil; Anthracycline failure; Breast cancer; Chemotherapy; Docetaxel; Methotrexate

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOCETAXEL; FLUOROURACIL; METHOTREXATE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EDEMA; FATIGUE; FEMALE; FLUID RETENTION; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEUROPATHY; PHASE 3 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA;

EID: 17344390083     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00122-7     Document Type: Article

References (17)

1. Clemons M., Leahy M., Valle J.et al. Review of recent trials of chemotherapy for advanced breast cancer. studies excluding taxanes Eur. J. Cancer. 33:1997;2171-2182.
2. Clemons M., Leahy M., Valle J.et al. Review of recent trials of chemotherapy for advanced breast cancer. the taxanes Eur. J. Cancer. 33:1997;2183-2193.
3. Van Oosterom A.T. Docetaxel (Taxotere) an effective agent in the management of second-line breast cancer. Semin. Oncol. 22:1995;22-28.
4. Porkka K., Blomqvist C., Rissanen P.et al. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J. Clin. Oncol. 12:1994;1639-1647.
5. Fisher B., Redmond C., Dimitrov N.V.et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N. Engl. J. Med. 320:1989;473-478.
6. Gewirtz A.M., Cadman E. Preliminary report on the efficacy of sequential methotrexate and 5-fluorouracil in advanced breast cancer. Cancer. 47:1981;2552-2555.
7. Herrmann R., Manegold C., Schroeder M.et al. Sequential methotrexate and 5-FU in breast cancer resistant to the conventional application of these drugs. Cancer Treat. Rep. 68:1984;1279-1281.
8. Kaye S.B., Sangster G., Hutcheon A.et al. Sequential methotrexate plus 5-FU in advanced breast and colorectal cancers. a phase II study Cancer Treat. Rep. 68:1984;547-548.
9. Perrault D.J., Erlichman C., Hasselback R.et al. Sequenced methotrexate (MTX) and 5-fluorouracil (5FU) in refractory metastatic breast cancer. a phase II study Proc. Am. Soc. Clin. Oncol. 2:1983;100.
10. Plotkin D., Waugh W.J. Sequential methotrexate-5-fluorouracil (MF) in advanced breast carcinoma. Proc. Am. Soc. Clin. Oncol. 1:1982;80.
11. Plotkin D., Ray M., Chien P. Sequential methotrexate-5-fluorouracil in advanced breast and colorectal cancers. a nonrandomized pilot study Proc. Am. Soc. Clin. Oncol. 7:1988;25.
12. Tisman G., Wu S.J. Effectiveness of intermediate-dose methotrexate and high-dose 5-fluorouracil as sequential combination chemotherapy in refractory breast cancer and as primary therapy in metastatic adenocarcinoma of the colon. Cancer Treat. Rep. 64:1980;829-835.
13. Miller A.B., Hoogstraten B., Staquet M.et al. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
14. Bruno R., Hille D., Riva A.et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J. Clin. Oncol. 16:1998;137-196.
15. Nabholtz J., Thuerlimann B., Bezwoda W.R.et al. Taxotere versus mitomycin C plus vinblastine in patients with metastatic breast cancer who have failed an anthracycline-containing regimen. Proc. Am. Soc. Clin. Oncol. 17:1998;390.
16. Chan S., Friedrichs K., Noel D.et al. A phase III study of Taxotere (T) versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen. Breast Cancer Research and Treatment. 23:1997;1.
17. Riva A., Fumoleau P., Roché H.et al. Efficacy and safety of different corticosteroid premedications in breast cancer patients treated with Taxotere® Proc. Am. Soc. Clin. Oncol. 16:1997;188a.